Eikon Therapeutics snares $500M series B, pinning constellation of biotech stars to its upper ranksnews2022-01-05T20:18:35+00:00January 5th, 2022|FierceBiotech|
Eli Lilly taps Entos’ delivery tech in $50M-plus nucleic acid pactnews2022-01-05T18:31:17+00:00January 5th, 2022|FierceBiotech|
Annexon shares dip 30% as patient dropouts dog midphase Huntington’s trialnews2022-01-05T17:52:12+00:00January 5th, 2022|FierceBiotech|
Ultragenyx granted go-ahead to up doses for Angelman antisense therapy that stalled after safety issuesnews2022-01-05T16:15:04+00:00January 5th, 2022|FierceBiotech|
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseasesnews2022-01-05T11:05:14+00:00January 5th, 2022|FierceBiotech|
Intellia bags option on autoimmune CAR-T prospect, handing Kyverna rights to use CRISPR tech to create off-the-shelf cell therapy news2022-01-05T10:56:30+00:00January 5th, 2022|FierceBiotech|
Exelixis nabs Merck veteran as chief medical officer on quest to expand its R&D footprintnews2022-01-04T14:04:29+00:00January 4th, 2022|FierceBiotech|
Transatlantic VC veterans tap Novo Holdings to raise $124M rare disease fundnews2022-01-04T10:41:45+00:00January 4th, 2022|FierceBiotech|
With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologiesnews2022-01-03T15:01:13+00:00January 3rd, 2022|FierceBiotech|
AstraZeneca taps Ionis to join crowd of companies gunning for rare heart disease in deal worth billions in biobucksnews2021-12-29T15:08:13+00:00December 29th, 2021|FierceBiotech|
